Assembly Biosciences Says Antiviral Drug Shows 'Encouraging' Phase 1 Results

MT Newswires Live

Dec 26, 2024

Assembly Biosciences (ASMB) said Thursday that an ongoing phase 1b study of its investigational antiviral drug ABI-4334 produced "encouraging" safety and efficacy results in patients with chronic hepatitis B virus.

The company cited improvements in trial-defined measures of antiviral activity in a study cohort that received an oral, once-daily 150 mg dose of ABI-4334 over 28 days.

The study also showed the drug was well-tolerated and had a favorable safety profile, the company said.

The biotechnology firm said it is now enrolling patients for a 400 mg daily trial cohort, with data expected to be released in H1 2025.

Following completion of the phase 1b study, Gilead Sciences (GILD) has the right to opt in to further development and commercialization of the drug, the company said.

Assembly Bio shares were up more than 1.5% in Thursday's premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2494868612"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2494868612\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2494868612?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-26 21:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2494868612","market":"hk","top_or_hot":-1,"title":"Assembly Biosciences Says Antiviral Drug Shows 'Encouraging' Phase 1 Results","media":"MT Newswires Live","content":"<html><body><p> Assembly Biosciences (ASMB) said Thursday that an ongoing phase 1b study of its investigational antiviral drug ABI-4334 produced \"encouraging\" safety and efficacy results in patients with chronic hepatitis B virus.</p><p>The company cited improvements in trial-defined measures of antiviral activity in a study cohort that received an oral, once-daily 150 mg dose of ABI-4334 over 28 days.</p><p>The study also showed the drug was well-tolerated and had a favorable safety profile, the company said.</p><p>The biotechnology firm said it is now enrolling patients for a 400 mg daily trial cohort, with data expected to be released in H1 2025.</p><p>Following completion of the phase 1b study, Gilead Sciences (GILD) has the right to opt in to further development and commercialization of the drug, the company said.</p><p>Assembly Bio shares were up more than 1.5% in Thursday's premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assembly Biosciences Says Antiviral Drug Shows 'Encouraging' Phase 1 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssembly Biosciences Says Antiviral Drug Shows 'Encouraging' Phase 1 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-26 21:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Assembly Biosciences (ASMB) said Thursday that an ongoing phase 1b study of its investigational antiviral drug ABI-4334 produced \"encouraging\" safety and efficacy results in patients with chronic hepatitis B virus.</p><p>The company cited improvements in trial-defined measures of antiviral activity in a study cohort that received an oral, once-daily 150 mg dose of ABI-4334 over 28 days.</p><p>The study also showed the drug was well-tolerated and had a favorable safety profile, the company said.</p><p>The biotechnology firm said it is now enrolling patients for a 400 mg daily trial cohort, with data expected to be released in H1 2025.</p><p>Following completion of the phase 1b study, Gilead Sciences (GILD) has the right to opt in to further development and commercialization of the drug, the company said.</p><p>Assembly Bio shares were up more than 1.5% in Thursday's premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富兰克林生物科技新领域基金A (acc)","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2494868612","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2494868612","pubTimestamp":1735220259,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Assembly Biosciences  said Thursday that an ongoing phase 1b study of its investigational antiviral drug ABI-4334 produced \"encouraging\" safety and efficacy results in patients with chronic hepatitis B virus.The company cited improvements in trial-defined measures of antiviral activity in a study cohort that received an oral, once-daily 150 mg dose of ABI-4334 over 28 days.The study also showed the drug was well-tolerated and had a favorable safety profile, the company said.The biotechnology firm said it is now enrolling patients for a 400 mg daily trial cohort, with data expected to be released in H1 2025.Following completion of the phase 1b study, Gilead Sciences  has the right to opt in to further development and commercialization of the drug, the company said.Assembly Bio shares were up more than 1.5% in Thursday's premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4578":"CAR-T","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4588":"碎股","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4583":"猴痘概念","ASMB":"Assembly Biosciences Inc.","LU0234570918.USD":"高盛全球核心股票组合Acc Close","BK4532":"文艺复兴科技持仓","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","GILD":"吉利德科学","BK4585":"ETF&股票定投概念","BK4139":"生物科技","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4566":"资本集团"},"translate_title":"Assembly Biosciences表示抗病毒药物显示出“令人鼓舞”的第一阶段结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":0.9,"ASMB":1},"content_text":"Assembly Biosciences (ASMB) said Thursday that an ongoing phase 1b study of its investigational antiviral drug ABI-4334 produced \"encouraging\" safety and efficacy results in patients with chronic hepatitis B virus.The company cited improvements in trial-defined measures of antiviral activity in a study cohort that received an oral, once-daily 150 mg dose of ABI-4334 over 28 days.The study also showed the drug was well-tolerated and had a favorable safety profile, the company said.The biotechnology firm said it is now enrolling patients for a 400 mg daily trial cohort, with data expected to be released in H1 2025.Following completion of the phase 1b study, Gilead Sciences (GILD) has the right to opt in to further development and commercialization of the drug, the company said.Assembly Bio shares were up more than 1.5% in Thursday's premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}